Print

Clinical Pharmacokinetic Data on TetraLogic Pharmaceuticals' Lead Smac Mimetic Birinapant Presented at American Society of Clinical Oncology  
6/4/2012 11:13:32 AM

MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a biopharmaceutical company developing a novel small molecule Smac mimetic drug to treat cancer, today announced that pharmacokinetic (PK) data from its lead investigational drug birinapant was featured at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 1 – 5, 2012 in Chicago, IL. The abstract was selected by ASCO’s Scientific Program Committee for presentation in a Poster Discussion Session. Clinical data demonstrates that birinapant has an excellent PK profile with dose-proportional kinetics as a single agent and in combination with standard-of-care chemotherapeutic agents. Birinapant is currently in Phase 2 clinical development for solid tumors, as well as in a Phase 1/2 study in acute myeloid leukemia (AML).
//-->